PubMed Health. A service of the National Library of Medicine, National Institutes of Health.
A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.
A.D.A.M. Medical Encyclopedia.
Thrombotic thrombocytopenic purpura (TTP) is a blood disorder that causes blood clots to form in small blood vessels around the body, and leads to a low platelet count (thrombocytopenia).
See also: Hemolytic-uremic syndrome
Causes, incidence, and risk factors
This disease may be caused by a lack of, or problems with, a certain enzyme (a type of protein) that is involved in blood clotting. These changes cause clotting to occur in an abnormal way.
- As the platelets clump together in these clots, fewer platelets are available in the blood in other parts of the body to help with clotting.
- This can lead to bleeding under the skin and purple-colored spots called purpura.
In some cases, the disorder is passed down through families (inherited) and patients are born with naturally low levels of this enzyme. This condition also may be related to:
- Cancer
- Hematopoietic stem cell transplantation
- Hormone replacement therapy and estrogens
- Medications (including ticlopidine, clopidogrel, guinine, and cyclosporine A)
Symptoms
- Bleeding into the skin or mucus membranes
- Heart rate over 100 beats per minute
- Purplish spots in the skin produced by small bleeding vessels near the surface of the skin (purpura)
- Speech changes
- Yellowish color to the skin (jaundice)
Signs and tests
- ADAMTS 13 activity level
- Creatinine level
- Lactate dehydrogenase (LDH) level
- Mucus membrane biopsy
- Von Willebrand factor electropheresis
Treatment
Plasma exchange (plasmapheresis plus infusion of donor plasma) is used to remove the antibodies that are affecting clotting from the blood and also replace the missing enzyme.
- First, you will have your blood drawn as if you were donating blood.
- The plasma portion of the blood will be passed through a cell separator. The remaining portion of the blood will be saved.
- Plasma will be added to it, and the blood will be returned to you through a transfusion.
This treatment is repeated daily until blood tests show improvement.
People who do not respond to this treatment or whose condition often returns may need to:
- Have surgery to remove their spleen
- Get drugs that suppress the immune system, such as corticosteroids or rituximab
Expectations (prognosis)
Plasma exchange has greatly improved the outcome of this disease. Most patients now recover completely. However, some people die from this disease, especially if it is not found immediately. In people who don't recover, this condition can become long-term (chronic).
Complications
- Low platelet count (thrombocytopenia)
- Low red blood cell count (caused by the premature breakdown of red blood cells)
- Nervous system problems
- Severe bleeding (hemorrhage)
Calling your health care provider
Call your health care provider if you have any unexplained bleeding.
Prevention
Because the cause is unknown, there is no known way to prevent this condition.
References
- McCrae KR, Sadler JE, Cines DB. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hoffman Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingstone Elsevier;2008:chap 139.
- Schafer A. Hemorrhagic disorders: Abnormalities of platelet and vascular function. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa:Saunders Elsevier;2007:chap 179.
Review Date: 2/28/2011.
Reviewed by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura
This review also showed that in patients with typical or diarrhoea associated haemolytic uraemic syndrome, there are no interventions that are superior to supportive therapy which includes control of fluid and electrolyte imbalance, use of dialysis if required, control of hypertension and blood transfusion as required.
The science behind screening testsScreening tests can lead to benefits and harms. Understand why, and how researchers find out if benefits outweigh harms for a test.
- Thrombotic thrombocytopenic purpuraThrombotic thrombocytopenic purpuraPubMed Health
Your browsing activity is empty.
Activity recording is turned off.
See more...